NCT04581512View on ClinicalTrials.gov

Study to Evaluate the Safety and Tolerability of EP0042

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 2, 2020

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2026

Conditions
Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

EP0042

EP0042 Oral 20 mg 50 mg capsules

DRUG

Venetoclax

Venetoclax

DRUG

Azacitidine (AZA)

Azacitidine

Trial Locations (6)

6000

RECRUITING

Royal Perth Hospital, Perth

1081HV Amsterdam

RECRUITING

Amsterdam UMC, Amsterdam

3000 CA Rotterdam

RECRUITING

Erasmus MC, Rotterdam

W1T 7HA

RECRUITING

University College London Hospital, London

Unknown

RECRUITING

The Royal Marsden, London

M204BX

RECRUITING

The Christie Hospital, Manchester

Sponsors

Lead Sponsor

Ellipses Pharma
All Listed Sponsors
lead

Ellipses Pharma

INDUSTRY